<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352608</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-nCOV-1001</org_study_id>
    <nct_id>NCT04352608</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅰ/Ⅱ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Research and Development Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blinded, and placebo controlled phase Ⅰ/Ⅱ clinical trial&#xD;
      of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research &amp; Development Co.,&#xD;
      Ltd. The purpose of this study is to evaluate the safety and immunogenicity of the&#xD;
      experimental vaccine in healthy adults aged 18~59 Years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blinded, single-center, placebo-controlled phase Ⅰ/Ⅱ&#xD;
      clinical trial in adults aged 18~59 years. The purpose of this study is to evaluate the&#xD;
      immunogenicity and safety of the experimental SARS-CoV-2 inactivated vaccine. The&#xD;
      experimental vaccine and placebo were both manufactured by Sinovac Research &amp; Development&#xD;
      Co., Ltd. A total of 744 subjects will be enrolled, with 144 at phase Ⅰ, and 600 at phase Ⅱ.&#xD;
      All of participants in phase Ⅰ will be assigned to receive two doses of experimental vaccine&#xD;
      or placebo on the schedule of day 0,14 or day 0,28.300 participants in phase Ⅱ will be&#xD;
      assigned to receive two doses of experimental vaccine or placebo on the schedule of day 0,14&#xD;
      or day 0,28 and one dose of booster immunization will be given 6 months after primary&#xD;
      immunization of day 0,14 or day 0,28.The other 300 participants in phase Ⅱ will be assigned&#xD;
      to receive three doses of experimental vaccine or placebo on the schedule of day 0,14,42 or&#xD;
      0,28,56 .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 10, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety indexes of adverse reactions</measure>
    <time_frame>From Day 0 to Day 28 after each dose</time_frame>
    <description>Incidence of adverse reactions occured from Day 0 to Day 28 after each dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity indexes of neutralizing-antibody seroconversion rates</measure>
    <time_frame>The 14th day /the 28th day after two doses of vaccination</time_frame>
    <description>The seroconversion rate of neutralizing antibodies 14 days (emergency schedule)/28 days (routine schedule) after the two-dose vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety indexes of adverse reactions</measure>
    <time_frame>7 days after each dose of vaccination</time_frame>
    <description>Incidence of adverse reactions 7 days after each dose of vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety indexes of Incidence of abnormal laboratory index</measure>
    <time_frame>On the 3th day after each dose of vaccination in phase Ⅰ</time_frame>
    <description>Incidence of abnormal laboratory index (blood routine test, blood chemistry test,and urine routine test) on the 3th day after each dose of vaccination in phase Ⅰ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety indexes of serious adverse events (SAEs）</measure>
    <time_frame>From the beginning of the vaccination to 6 months post the whole-schedule vaccination</time_frame>
    <description>Incidence of SAEs from the beginning of the vaccination to 6 months post the whole-schedule vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indexes of the seropositive rate, GMT, and GMI of neutralizing antibodies</measure>
    <time_frame>14 days (emergency schedule)/28 days (routine schedule) after two-dose vaccination</time_frame>
    <description>The seropositive rate, GMT, and GMI of neutralizing antibodies 14 days (emergency schedule)/28 days (routine schedule) after two-dose vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indexes of the seroconversion rate, seropositive rate, GMT and GMI of neutralizing antibodies</measure>
    <time_frame>28 days after the two doses (emergency schedule)</time_frame>
    <description>The seroconversion rate, seropositive rate, GMT and GMI of neutralizing antibodies 28 days after the two doses (emergency schedule)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indexes of the seroconversion rate, seropositive rate, GMT, and GMI in Phase Ⅱ</measure>
    <time_frame>28 days after the third dose （only for days 0,14,42 and days 0,28,56 schedule）</time_frame>
    <description>Phase Ⅱ:The seroconversion rate, seropositive rate, GMT, and GMI 28 days after the third dose（only for days 0,14,42 and days 0,28,56 schedule）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indexes of the seropositivity rate, GMT, and GMI in Phase Ⅱ</measure>
    <time_frame>14 day (emergency schedule)/28 days (routine schedule) after the booster dose （only for days 0,14 and days 0,28 schedule）</time_frame>
    <description>Phase Ⅱ:The seropositivity rate, GMT, and GMI 14 day (emergency schedule)/28 days (routine schedule) after the booster dose （only for days 0,14 and days 0,28 schedule）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indexes of the seroconversion rate, seropositive rate, GMT, and GMI in Phase Ⅰ</measure>
    <time_frame>7/14/21 days after the first dose vaccination (emergency schedule)</time_frame>
    <description>Phase Ⅰ:The seroconversion rate, seropositive rate, GMT, and GMI 7/14/21 days after the first dose vaccination (emergency schedule)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indexes of the seroconversion rate, seropositive rate, GMT, and GMI in Phase Ⅰ</measure>
    <time_frame>28/35/42 days after the first dose vaccination (routine schedules)</time_frame>
    <description>Phase Ⅰ:The seroconversion rate, seropositive rate, GMT, and GMI 28/35/42 days after the first dose vaccination (routine schedules)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indexes of the seropositive rate of IgG, IgM antibodies</measure>
    <time_frame>7/14/21/28/42 days after the first dose vaccination (emergency schedule)</time_frame>
    <description>Phase Ⅰ:The seropositive rate of IgG, IgM antibodies 7/14/21/28/42 days after the first dose vaccination (emergency schedule)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity indexes of the seropositive rate of IgG,IgM antibodies</measure>
    <time_frame>28/35/42/56 days after the first dose vaccination (routine schedule)</time_frame>
    <description>Phase Ⅰ: The seropositive rate of IgG,IgM antibodies 28/35/42/56 days after the first dose vaccination (routine schedule)</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">744</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Emergency schedule &amp; Two doses of medium dosage vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the emergency schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emergency schedule &amp; Two doses of high dosage vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the emergency schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emergency schedule &amp;Two doses of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the emergency vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the emergency schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine schedule &amp; Two doses of medium dosage vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the routine schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine schedule &amp;Two doses of high dosage vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the routine schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine schedule &amp; Two doses of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the routine vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the routine schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emergency schedule &amp; Three doses of medium dosage vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emergency schedule &amp; Three doses of high dosage vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emergency schedule &amp;Three doses of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 participants in phase Ⅱ will receive three doses of placebo at the emergency vaccination schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine schedule &amp; Three doses of medium dosage vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine schedule &amp;Three doses of high dosage vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine schedule &amp;Three doses of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 participants in phase Ⅱ will receive three doses of placebo at the routine vaccination schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule</intervention_name>
    <description>Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.</description>
    <arm_group_label>Emergency schedule &amp; Two doses of medium dosage vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule</intervention_name>
    <description>Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.</description>
    <arm_group_label>Emergency schedule &amp; Two doses of high dosage vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Two doses of placebo at the emergency vaccination schedule</intervention_name>
    <description>Two doses of placebo at the schedule of day 0,14 and one dose of booster immunization with placebo 6 months after the schedule of day 0,14 in phaseⅡ.</description>
    <arm_group_label>Emergency schedule &amp;Two doses of placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule</intervention_name>
    <description>Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ.</description>
    <arm_group_label>Routine schedule &amp; Two doses of medium dosage vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule</intervention_name>
    <description>Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ</description>
    <arm_group_label>Routine schedule &amp;Two doses of high dosage vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Two doses of placebo at the routine vaccination schedule</intervention_name>
    <description>Two doses of placebo at the schedule of day 0,28 and one dose of booster immunization with placebo 6 months after the schedule of day 0,28 in phaseⅡ.</description>
    <arm_group_label>Routine schedule &amp; Two doses of placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule</intervention_name>
    <description>Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,42</description>
    <arm_group_label>Emergency schedule &amp; Three doses of medium dosage vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule</intervention_name>
    <description>Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14,42</description>
    <arm_group_label>Emergency schedule &amp; Three doses of high dosage vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of placebo at the emergency vaccination schedule</intervention_name>
    <description>Three doses of placebo at the schedule of day 0,14,42</description>
    <arm_group_label>Emergency schedule &amp;Three doses of placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule</intervention_name>
    <description>Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,56</description>
    <arm_group_label>Routine schedule &amp; Three doses of medium dosage vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule</intervention_name>
    <description>Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28,56</description>
    <arm_group_label>Routine schedule &amp;Three doses of high dosage vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Three doses of placebo at the routine vaccination schedule</intervention_name>
    <description>Three doses of placebo at the schedule of day 0,28,56</description>
    <arm_group_label>Routine schedule &amp;Three doses of placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 18-59 years;&#xD;
&#xD;
          -  Proven legal identity;&#xD;
&#xD;
          -  Participants should be capable of understanding the informed consent form, and such&#xD;
             form should be signed prior to enrolment ;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Travel history / residence history of Wuhan city and surrounding areas, or other&#xD;
             communities with case reports within 14 days;&#xD;
&#xD;
          -  History of contact with a SARS-CoV-2 infection (positive in nucleic acid test) within&#xD;
             14 days;&#xD;
&#xD;
          -  Have contacted patients with fever or respiratory symptoms from Wuhan and surrounding&#xD;
             areas, or from communities with case reports within 14 days;&#xD;
&#xD;
          -  Have contacted patients with fever or respiratory symptoms from Wuhan and surrounding&#xD;
             areas, or from communities with case reports within 14 days;&#xD;
&#xD;
          -  Self-reported history of SARS;&#xD;
&#xD;
          -  Self-reported history of new coronavirus infection;&#xD;
&#xD;
          -  Positive in serum antibodies (IgG or IgM) screening of COVID-19;&#xD;
&#xD;
          -  Positive in nasopharyngeal swabs or anal swabs through RT-PCR;&#xD;
&#xD;
          -  Women who are breastfeeding, pregnant or planning to become pregnant during the study&#xD;
             period;&#xD;
&#xD;
          -  BMI≥35 kg/m2;&#xD;
&#xD;
          -  History of asthma, history of allergy to the vaccine or vaccine components, or serious&#xD;
             adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema;&#xD;
&#xD;
          -  Congenital malformations or developmental disorders, genetic defects, severe&#xD;
             malnutrition, etc.;&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency / immunosuppression;&#xD;
&#xD;
          -  Suffering from severe chronic diseases, severe cardiovascular diseases, hypertension&#xD;
             and diabetes that cannot be controlled by drugs, liver and kidney diseases, malignant&#xD;
             tumors, etc.;&#xD;
&#xD;
          -  Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;&#xD;
&#xD;
          -  Thyroid disease or history of thyroidectomy, spleenlessness, functional&#xD;
             spleenlessness, spleenlessness or splenectomy resulting from any condition;&#xD;
&#xD;
          -  Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors,&#xD;
             blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;&#xD;
&#xD;
          -  Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding&#xD;
             allergic rhinitis corticosteroid spray therapy, acute non-complicated dermatitis&#xD;
             superficial corticosteroid therapy) in the past 6 months;&#xD;
&#xD;
          -  Abnormal laboratory test results in the physical examination such as clinically&#xD;
             significant abnormal hematology and biochemistry beyond the reference value range&#xD;
             (only applicable to Phase I clinical trials);&#xD;
&#xD;
          -  History of alcohol or drug abuse;&#xD;
&#xD;
          -  Receipt of blood products within in the past 3 months;&#xD;
&#xD;
          -  Receipt of other investigational drugs in the past 30 days;&#xD;
&#xD;
          -  Receipt of attenuated live vaccines in the past 14 days;&#xD;
&#xD;
          -  Receipt of inactivated or subunit vaccines in the past 7 days;&#xD;
&#xD;
          -  Attacks of acute diseases or chronic diseases in the past 7 days;&#xD;
&#xD;
          -  Axillary temperature &gt;37.0°C;&#xD;
&#xD;
          -  According to the investigator's judgment, the subject has any other factors that are&#xD;
             not suitable for participating in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengcai Zhu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Suining County Center for Disease Control and Prevention</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

